You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NHLBI

    Summary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

    SBC: NYTRICX INC            Topic: NHLBI

    Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. F plus G RSV VLP Vaccine for Improved Safety and Efficacy

    SBC: RAZI PHARMA LLC            Topic: NIAID

    Project Summary Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants and young children worldwide. Since infection induces only partial protection, it causes repeat infection and disease throughout life. Though a high priority for vaccine development no vaccine is yet available. The lack of success in developing a vaccine suggests novel strateg ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Neural Stem Cell Extracellular Vesicle Treatment for Traumatic Brain Injury

    SBC: ARUNA BIO, INC.            Topic: NINDS

    Project Summary/AbstractTraumatic brain injury (TBI) is a universal health concern and is known as a “silent epidemic”. Each year in America, 2.53 million patients visit the emergency department after suffering a TBI of which 56,800 die and over 288,000 require hospitalization, rehabilitation programs, and long-term supportive care. Although the primary TBI event is typically acute, subsequent ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Colon cancer prevention with non-systemic PDE5 inhibitors

    SBC: Targut Biotechnologies Inc.            Topic: 102

    Approximately 50,000 people will die from colorectal cancer (CRC) in the United States this year due to the late stage at diagnosis where treatments are largely ineffective. Primary prevention of CRC is therefore very important for high-risk patients. Chemoprevention agents are needed for CRC but nothing has been approved for this purpose. Extensive preclinical and epidemiological evidence show gr ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of the UValidate platform for the profiling of topically applied chemical agents.

    SBC: AMELIA TECHNOLOGIES LLC            Topic: R

    Project Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer

    SBC: PAZ PHARMACEUTICALS LLC            Topic: NCI

    Summary Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the U.S. with a 5-year survival rate of andlt;9%. The poor prognosis is partially due to resistance to standard of care treatments including gemcitabine (Gem) and Gem+nab-paclitaxel (n-PTX). The transcription factors HIF-1α and c-MYC are at the center of the mechanisms producing Gem and n-PTX resistance ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. A Precision Medicine Tool for Optimal Personalized Treatment in Patients with Acute Myeloid Leukemia

    SBC: SANICKA, INC            Topic: NCI

    Acute myeloid leukemia (AML) is an aggressive cancer of the bone marrow and peripheral blood with poor prognosis mostly due to relapse. Despite decades of improvements in chemo-immunotherapy (CIT) and, more recently, the use of hypomethylating agent (HMAs) and addition of novel small molecule inhibitors (SMIs) to back-bone chemotherapy, AML treatment selection and dosage remains mostly empiric, wi ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Simulated Exposure Trainer (SET-VR): Implementing Targeted Experiential Training with a Virtual Patient

    SBC: VIRTUALLY BETTER INC            Topic: 104

    PROJECT SUMMARY/ABSTRACT Despite the existence of numerous, well-established evidence-based practices (EBPs) for mental disorders, it has been difficult to disseminate these practices in community settings. Exposure therapy for anxiety disorders represents one of the most glaring examples of this research-to-practice gap. Just as patients are anxious about approaching their fears, therapists are o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility study of novel hand hygiene formulations against bacterial spore infection

    SBC: CAMELLIX, LLC            Topic: NIAID

    Project Summary: Spore-forming bacterial species, such as various Bacilli and Clostridia, undergo a sporulation process under unfavorable conditions to form dormant spores. These bacterial spores have become a threat to the food industry as they can cause food spoilage and food poisoning. In addition, an opportunistic pathogen, Clostridium difficile (C. difficile), one of the five CDC- listed urge ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government